Fig. 1From: Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trialStudy flow-chart with number of patients screened, randomized and included in the final analysisBack to article page